Genetically engineered knock-in and conditional knock-in mouse models of cancer

Cold Spring Harbor Protocols

Volumn 2014, Issue 9, 2014, Pages 897-911

  Rappaport, Amy ^a   Johnson, Leisa ^a  

^a GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; GENE CONTROL; GENE EXPRESSION; GENE FREQUENCY; GENE LOCUS; GENE MUTATION; GENE OVEREXPRESSION; GENETIC ENGINEERING; GENETIC TRANSCRIPTION; HUMAN; NEOPLASM; ANIMAL; DISEASE MODEL; GENETICS; MOUSE; MUTATION; TRANSGENIC MOUSE;

TUMOR MARKER;

ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; MICE; MICE, TRANSGENIC; MUTATION; NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84923928065     PISSN: 19403402     EISSN: 15596095     Source Type: Journal    
DOI: 10.1101/pdb.top069799     Document Type: Article

References (66)

1. Adams JM, Cory S. 1991. Transgenic models of tumor development. Science 254: 1161–1167.
2. Aguirre AJ, Bardeesy N, Sinha M, Lopez L, Tuveson DA, Horner J, Redston MS, DePinho RA. 2003. Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma. Genes Dev 17: 3112–3126.
3. Braun BS, Tuveson DA, Kong N, Le DT, Kogan SC, Rozmus J, Le Beau MM, Jacks TE, Shannon KM. 2004. Somatic activation of oncogenic Kras in hematopoietic cells initiates a rapidly fatal myeloproliferative disorder. Proc Natl Acad Sci 101: 597–602.
4. Brocard J, Warot X, Wendling O, Messaddeq N, Vonesch JL, Chambon P, Metzger D. 1997. Spatio-temporally controlled site-specific somatic mutagenesis in the mouse. Proc Natl Acad Sci 94: 14559–14563.
5. Cade L, Reyon D, Hwang WY, Tsai SQ, Patel S, Khayter C, Joung JK, Sander JD, Peterson RT, Yeh JR. 2012. Highly efficient generation of heritable zebrafish gene mutations using homo- and heterodimeric TALENs. Nucleic Acids Res 40: 8001–8010.
6. Carbery ID, Ji D, Harrington A, Brown V, Weinstein EJ, Liaw L, Cui X. 2010. Targeted genome modification in mice using zinc-finger nucleases. Genetics 186: 451–459.
7. Carroll D. 2011. Genome engineering with zinc-finger nucleases. Genetics 188: 773–782.
8. Caulin C, Nguyen T, Lang GA, Goepfert TM, Brinkley BR, Cai W-W, Lozano G, Roop DR. 2007. An inducible mouse model for skin cancer reveals distinct roles for gain- and loss-of-function p53 mutations. J Clin Invest 117: 1893–1901.
9. Cristea S, Gregory PD, Urnov FD, Cost GJ. 2011. Dissection of splicing regulation at an endogenous locus by zinc-finger nuclease-mediated gene editing. PLoS One 6: e16961.
10. Cui X, Ji D, Fisher DA, Wu Y, Briner DM, Weinstein EJ. 2011. Targeted integration in rat and mouse embryos with zinc-finger nucleases. Nat Biotechnol 29: 64–67.
11. Dankort D, Filenova E, Collado M, Serrano M, Jones K, Mcmahon M. 2007. A new mouse model to explore the initiation, progression, and therapy of BRAFV600E-induced lung tumors. Genes Dev 21: 379–384.
12. Dankort D, Curley DP, Cartlidge RA, Nelson B, Karnezis AN, Damsky WE Jr, You MJ, DePinho RA, McMahon M, Bosenberg M. 2009. Braf V600E cooperates with Pten loss to induce metastatic melanoma. Nat Genetics 41: 544–552.
13. Davis D, Stokoe D. 2010. Zinc finger nucleases as tools to understand and treat human diseases. BMC Med 8: 42.
14. Gabriel R, Lombardo A, Arens A, Miller JC, Genovese P, Kaeppel C, Nowrouzi A, Bartholomae CC, Wang J, Friedman G, et al. 2011. An unbiased genome-wide analysis of zinc-finger nuclease specificity. Nat Biotechnol 29: 816–823.
15. Guerra C, Mijimolle N, Dhawahir A, Dubus P, Barradas M, Serrano M, Campuzano V, Barbacid M. 2003. Tumor induction by an endogenous K-ras oncogene is highly dependent on cellular context. Cancer Cell 4: 111–120.
16. Gutschner T, Baas M, Diederichs S. 2011. Noncoding RNA gene silencing through genomic integration of RNA destabilizing elements using zinc finger nucleases. Genome Res 21: 1944–1954.
17. Haigis KM, Kendall KR, Wang Y, Cheung A, Haigis MC, Glickman JN, Niwa-Kawakita M, Sweet-Cordero A, Sebolt-Leopold J, Shannon KM, et al. 2008. Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon. Nat Genet 40: 600–608.
18. Hasty P, Ramirez-Solis R, Krumlauf R, Bradley A. 1991. Introduction of a subtle mutation into the Hox-2.6 locus in embryonic stem cells. Nature 350: 243–246.
19. Hingorani SR, Petricoin EF, Maitra A, Rajapakse V, King C, Jacobetz MA, Ross S, Conrads TP, Veenstra TD, Hitt BA, et al. 2003. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell 4: 437–450.
20. Hingorani SR, Wang L, Multani AS, Combs C, Deramaudt TB, Hruban RH, Rustgi AK, Chang S, Tuveson DA. 2005. Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell 7: 469–483.
21. Hockemeyer D, Wang H, Kiani S, Lai CS, Gao Q, Cassady JP, Cost GJ, Zhang L, Santiago Y, Miller JC, et al. 2011. Genetic engineering of human pluripotent cells using TALE nucleases. Nat Biotechnol 29: 731–734.
22. Huang P, Xiao A, Zhou M, Zhu Z, Lin S, Zhang B. 2011. Heritable gene targeting in zebrafish using customized TALENs. Nat Biotechnol 29: 699–700.
23. Hung KE, Maricevich MA, Richard LG, Chen WY, Richardson MP, Kunin A, Bronson RT, Mahmood U, Kucherlapati R. 2010. Development of a mouse model for sporadic and metastatic colon tumors and its use in assessing drug treatment. Proc Natl Acad Sci 107: 1565–1570.
24. Ijichi H, Chytil A, Gorska AE, Aakre ME, Fujitani Y, Fujitani S, Wright CV, Moses HL. 2006. Aggressive pancreatic ductal adenocarcinoma in mice caused by pancreas-specific blockade of transforming growth factorbeta signaling in cooperation with active Kras expression. Genes Dev 20: 3147–3160.
25. Isalan M, Klug A, Choo Y. 2001. A rapid, generally applicable method to engineer zinc fingers illustrated by targeting the HIV-1 promoter. Nat Biotechnol 19: 656–660.
26. Jackson EL, Willis N, Mercer K, Bronson RT, Crowley D, Montoya R, Jacks T, Tuveson DA. 2001. Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev 15: 3243–3248.
27. Ji H, Ramsey MR, Hayes DN, Fan C, McNamara K, Kozlowski P, Torrice C, Wu MC, Shimamura T, Perera SA, et al. 2007. LKB1 modulates lung cancer differentiation and metastasis. Nature 448: 807–810.
28. Johnson L, Mercer K, Greenbaum D, Bronson RT, Crowley D, Tuveson DA, Jacks T. 2001. Somatic activation of the K-ras oncogene causes early onset lung cancer in mice. Nature 410: 1111–1116.
29. Joung JK, Sander JD. 2012. TALENs: A widely applicable technology for targeted genome editing. Nat Rev Mol Cell Biol 14: 49–55.
30. Kim JH, Lee SR, Li LH, Park HJ, Park JH, Lee KY, Kim MK, Shin BA, Choi SY. 2011. High cleavage efficiency of a 2A peptide derived from porcine teschovirus-1 in human cell lines, zebrafish and mice. PLoS One 6: e18556.
31. Kinross KM, Montgomery KG, Kleinschmidt M, Waring P, Ivetac I, Tikoo A, Saad M, Hare L, Roh V, Mantamadiotis T, et al. 2012. An activating Pik3ca mutation coupled with Pten loss is sufficient to initiate ovarian tumorigenesis in mice. J Clin Invest 122: 553–557.
32. Kirsch DG, Dinulescu DM, Miller JB, Grimm J, Santiago PM, Young NP, Nielsen GP, Quade BJ, Chaber CJ, Schultz CP, et al. 2007. A spatially and temporally restricted mouse model of soft tissue sarcoma. Nat Med 13: 992–997.
33. Kitayama H, Tsujimura T, Matsumura I, Oritani K, Ikeda H, Ishikawa J, Okabe M, Suzuki M, Yamamura K, Matsuzawa Y, et al. 1996. Neoplastic transformation of normal hematopoietic cells by constitutively activating mutations of c-kit receptor tyrosine kinase. Blood 88: 995–1004.
34. Lakso M, Sauer B, Mosinger B Jr, Lee EJ, Manning RW, Yu SH, Mulder KL, Westphal H. 1992. Targeted oncogene activation by site-specific recombination in transgenic mice. Proc Natl Acad Sci 89: 6232–6236.
35. Lang GA, Iwakuma T, Suh Y-A, Liu G, Rao VA, Parant JM, Valentin-Vega YA, Terzian T, Caldwell LC, Strong LC, et al. 2004. Gain of function of a p53 hot spot mutation in a mouse model of Li–Fraumeni syndrome. Cell 119: 861–872.
36. Lombardo A, Genovese P, Beausejour CM, Colleoni S, Lee YL, Kim KA, Ando D, Urnov FD, Galli C, Gregory PD, et al. 2007. Gene editing in human stem cells using zinc finger nucleases and integrase-defective lentiviral vector delivery. Nat Biotechnol 25: 1298–1306.
37. Lyons SK, Patrick PS, Brindle KM. 2013. Imaging mouse cancer models in vivo using reporter transgenes. Cold Spring Harb Protoc doi:10.1101/pdb.top069864.
38. Maeder ML, Thibodeau-Beganny S, Osiak A, Wright DA, Anthony RM, Eichtinger M, Jiang T, Foley JE, Winfrey RJ, Townsend JA, et al. 2008. Rapid “open-source” engineering of customized zinc-finger nucleases for highly efficient gene modification. Mol Cell 31: 294–301.
39. Martin P, Albagli O, Poggi MC, Boulukos KE, Pognonec P. 2006. Development of a new bicistronic retroviral vector with strong IRES activity. BMC Biotechnol 6: 4.
40. Mercer K, Giblett S, Green S, Lloyd D, Darocha Dias S, Plumb M, Marais R, Pritchard C. 2005. Expression of endogenous oncogenic V600EB-raf induces proliferation and developmental defects in mice and transformation of primary fibroblasts. Cancer Res 65: 11493–11500.
41. Meuwissen R, Linn SC, Van Der Valk M, Mooi WJ, Berns A. 2001. Mouse model for lung tumorigenesis through Cre/lox controlled sporadic activation of the K-Ras oncogene. Oncogene 20: 6551–6558.
42. Meyer M, De Angelis MH, Wurst W, Kuhn R. 2010. Gene targeting by homologous recombination in mouse zygotes mediated by zinc-finger nucleases. Proc Natl Acad Sci 107: 15022–15026.
43. Moehle EA, Rock JM, Lee YL, Jouvenot Y, Dekelver RC, Gregory PD, Urnov FD, Holmes MC. 2007. Targeted gene addition into a specified location in the human genome using designed zinc finger nucleases. Proc Natl Acad Sci 104: 3055–3060.
44. Murphy DJ, Junttila MR, Pouyet L, Karnezis A, Shchors K, Bui DA, Brown- Swigart L, Johnson L, Evan GI. 2008. Distinct thresholds govern Myc’s biological output in vivo. Cancer Cell 14: 447–457.
45. Mussolino C, Cathomen T. 2012. TALE nucleases: Tailored genome engineering made easy. Curr Opin Biotechnol 23: 644–650.
46. Nakai N, Ishikawa T, Nishitani A, Liu N-N, Shincho M, Hao H, Isozaki K, Kanda T, Nishida T, Fujimoto J, et al. 2007. A mouse model of a human multiple GIST family with KIT-Asp820Tyr mutation generated by a knock-in strategy. J Pathol 214: 302–311.
47. Olive KP, Tuveson DA, Ruhe ZC, Yin B, Willis NA, Bronson RT, Crowley D, Jacks T. 2004. Mutant p53 gain of function in two mouse models of Li–Fraumeni syndrome. Cell 119: 847–860.
48. Pattanayak V, Ramirez CL, Joung JK, Liu DR. 2011. Revealing off-target cleavage specificities of zinc-finger nucleases by in vitro selection. Nat Methods 8: 765–770.
49. Perez-Mancera PA, Guerra C, Barbacid M, Tuveson DA. 2012. What we have learned about pancreatic cancer from mouse models. Gastroenterology 142: 1079–1092.
50. Pollock R, Giel M, Linher K, Clackson T. 2002. Regulation of endogenous gene expression with a small-molecule dimerizer. Nat Biotechnol 20: 729–733.
51. Rémy S, Tesson L, Ménoret S, Usal C, Scharenberg AM, Anegon I. 2009. Zinc-finger nucleases: A powerful tool for genetic engineering of animals. Transgenic Res 19: 363–371.
52. Ramirez CL, Certo MT, Mussolino C, Goodwin MJ, Cradick TJ, Mccaffrey AP, Cathomen T, Scharenberg AM, Joung JK. 2012. Engineered zinc finger nickases induce homology-directed repair with reduced mutagenic effects. Nucleic Acids Res 40: 5560–5568.
53. Reyon D, Khayter C, Regan MR, Joung JK, Sander JD. 2012a. Engineering designer transcription activator-like effector nucleases (TALENs) by REAL or REAL-Fast assembly. Curr Protoc Mol Biol Chapter 12: 12.15.1–12.15.14. doi: 10.1002/0471142727.mb1215s100.
54. Reyon D, Tsai SQ, Khayter C, Foden JA, Sander JD, Joung JK. 2012b. FLASH assembly of TALENs for high-throughput genome editing. Nat Biotechnol 30: 460–465.
55. Sander JD, Dahlborg EJ, Goodwin MJ, Cade L, Zhang F, Cifuentes D, Curtin SJ, Blackburn JS, Thibodeau-Beganny S, Qi Y, et al. 2011a. Selectionfree zinc-finger-nuclease engineering by context-dependent assembly (CoDA). Nat Methods 8: 67–69.
56. Sander JD, Maeder ML, Joung JK. 2011b. Engineering designer nucleases with customized cleavage specificities. Curr Protoc Mol Biol Chapter 12: Unit12 13.
57. Smith HW, Muller WJ. 2013. Transgenic mouse models—A seminal breakthrough in oncogene research. Cold Spring Harb Protoc doi:10.1101/pdb.top069765.
58. Snyder EL, Watanabe H, Magendantz M, Hoersch S, Chen TA, Wang DG, Crowley D, Whittaker CA, Meyerson M, Kimura S, et al. 2013. Nkx2–1 represses a latent gastric differentiation program in lung adenocarcinoma. Mol Cell 50: 185–199.
59. Sommer G, Agosti V, Ehlers I, Rossi F, Corbacioglu S, Farkas J, Moore M, Manova K, Antonescu CR, Besmer P. 2003. Gastrointestinal stromal tumors in a mouse model by targeted mutation of the Kit receptor tyrosine kinase. Proc Natl Acad Sci 100: 6706–6711.
60. Thomas KR, Capecchi MR. 1987. Site-directed mutagenesis by gene targeting in mouse embryo-derived stem cells. Cell 51: 503–512.
61. Tikoo A, Roh V, Montgomery KG, Ivetac I, Waring P, Pelzer R, Hare L, Shackleton M, Humbert P, Phillips WA. 2012. Physiological levels of Pik3caH1047R mutation in the mouse mammary gland results in ductal hyperplasia and formation of ERα-positive tumors. PLoS One 7: e36924.
62. Wang J, Abate-Shen C. 2014. Analyses of tumor suppressor genes in germline mouse models of cancer. Cold Spring Harb Protoc doi:10.1101/pdb.top069773.
63. Weber E, Gruetzner R, Werner S, Engler C, Marillonnet S. 2011. Assembly of designer TAL effectors by Golden Gate cloning. PLoS One 6: e19722.
64. Young NP, Crowley D, Jacks T. 2011. Uncoupling cancer mutations reveals critical timing of p53 loss in sarcomagenesis. Cancer Res 71: 4040–4047.
65. Yuan W, Stawiski E, Janakiraman V, Chan E, Durinck S, Edgar KA, Kljavin NM, Rivers CS, Gnad F, Roose-Girma M, et al. 2012. Conditional activation of Pik3caH1047R in a knock-in mouse model promotes mammary tumorigenesis and emergence of mutations. Oncogene 32: 318–326.
66. Zhu H, Acquaviva J, Ramachandran P, Boskovitz A, Woolfenden S, Pfannl R, Bronson RT, Chen JW, Weissleder R, Housman DE, et al. 2009. Oncogenic EGFR signaling cooperates with loss of tumor suppressor gene functions in gliomagenesis. Proc Natl Acad Sci 106: 2712–2716.